The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BOLT | -59.5% | N/A | N/A | -99% |
| S&P | +14.18% | +88.25% | +13.47% | +76% |
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.17M | 90.1% |
| Gross Profit | $1.88M | 168.0% |
| Gross Margin | 86.63% | 25.2% |
| Market Cap | $10.21M | -58.8% |
| Market Cap / Employee | $0.20M | 0.0% |
| Employees | 52 | -48.0% |
| Net Income | -$7.14M | 52.9% |
| EBITDA | -$7.41M | 53.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $18.54M | 82.5% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $20.89M | 36.1% |
| Short Term Debt | $2.70M | -4.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -48.95% | -3.2% |
| Return On Invested Capital | -77.57% | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$9.80M | 30.0% |
| Operating Free Cash Flow | -$9.73M | 30.3% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.36 | 0.33 | 0.24 | 0.26 | -23.64% |
| Price to Sales | 2.66 | 4.22 | 2.66 | 1.97 | -22.45% |
| Price to Tangible Book Value | 5.69 | 5.36 | 0.24 | 0.26 | -96.18% |
| Enterprise Value to EBITDA | 0.16 | -0.04 | 0.03 | -0.15 | -120.54% |
| Return on Equity | -74.3% | -83.9% | -81.3% | -82.0% | 26.13% |
| Total Debt | $25.21M | $24.71M | $24.18M | $23.59M | 29.77% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
